You searched for:"Manuel Maurício Gonçalves"
We found (2) results for your search.Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1998;20(9):509-515
DOI 10.1590/S0100-72031998000900004
Purpose: to evaluate the efficacy of four antibiotic regimens in puerperal infection prophylaxis. Patients and Methods: According to vaginal or abdominal delivery and risk the presence or not of factors for puerperal infection, the patients were allocated to groups of low, medium and high risk for its development. Between March 1994 and June 1997 2,263 patients were evaluated. Results: the incidence of puerperal infection was different in each group. It was 3.1% in the low risk group, where no antibiotic was given, and 8.5% in the high risk group where all patients received three doses of 1 g EV cefalotin at six-hour intervals. In the medium risk group, the incidence of puerperal infection was 5.3% for the patients who used three doses of 1 g EV cefoxitin; 5.1% for those who used three doses of 1 g EV cefalotin; 4.0% when a single cefoxitin dose was used and 3.4% when a single cefalotin dose was used. Conclusions: it is not necessary to use prophylactic antibiotic therapy in low risk patients and the first generation cephalosporins (cefalotin) are as efficacious as the second generation cephalosporins (cefoxitin) to prevent puerperal infection, independent of the applied dosage. Cefalotin seems to be effective in preventing puerperal infection in patients at high risk.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1998;20(8):457-462
DOI 10.1590/S0100-72031998000800005
Objective: to determine the efficacy and safety of misoprostol for cervical ripening and induction of labor in pregnant women at term when compared with placebo. Patients and Methods: fifty-one high-risk pregnant women at term, with unripe cervix, were allocated in a double-blind trial for treatment with intravaginal misoprostol (40 mg, 4/4 h) or intravaginal placebo. Results: thirty-two patients received misoprostol and 19 received placebo. The groups were homogeneous concerning maternal age, gestacional age, parity, and indication for induction (p > 0.05). In the misoprostol group the efficacy was 87.5% and in the placebo group 21.1% (p = 0.0000087). Regarding delivery, in the misoprostol group 75% had vaginal delivery and 25% abdominal delivery, and in the placebo group only 32% had vaginal delivery and 68% abdominal delivery (p = 0.0059).The Apgar score was similar. Conclusion: in this study misoprostol was effective and safe for cervical ripening and induction of labor.